Robert P. Dellavalle, MD, PhD, MSPH
Correspondence information about the author MD, PhD, MSPH Robert P. Dellavalle
Email the author MD, PhD, MSPH Robert P. Dellavalle
Correspondence information about the author MD, PhD, MSPH Robert P. DellavalleEmail the author MD, PhD, MSPH Robert P. Dellavalle
Article Info
Twenty-eight states currently allow for comprehensive public medical cannabis programs, and this number continues to grow.1 Approximately 1 in 10 adult cannabis users in the United States use it for medical purposes.
2 Numerous studies have investigated its uses for chronic pain, spasticity, anorexia, and nausea.
In recent years, researchers have also investigated its use for the treatment of dermatologic conditions including pruritus, inflammatory skin disease, and skin cancer.
Key words:
cannabinoid, cannabis, dermatitis, endocannabinoid, inflammatory skin disease, keratinocyte carcinoma, melanoma, palmitoylethanolamide, pruritus, skin cancer, tetrahydrocannabinol
Abbreviations used:
CB1 (cannabinoid 1), CB2 (cannabinoid 2), PEA (palmitoylethanolamide), THC (tetrahydrocannabinol)
Ms Mounessa and Ms Siegel contributed equally to this article.
Funding sources: None.
Conflicts of interest: None declared.
Reprints not available from the authors.
Funding sources: None.
Conflicts of interest: None declared.
Reprints not available from the authors.
© 2017 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
